|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Patient-reported event** | Baseline (N=20) | 3 months (N=20) | 6 months (N=20) | 12 months (N=10) | p |
| **FREQUENCY** |
| Abdominal pain  | 20% | 60% | 50% | 50% | 0.06 |
| Alopecia | 15% | 35% | 45% | 30% | 0.23 |
| Arthralgia | 50% | 80% | 75% | 60% | 0.18 |
| Constipation | 50% | 70% | 55% | 60% | 0.63 |
| Diarrhoea | 25% | 40% | 45% | 70% | 0.14 |
| Headache | 50% | 35% | 55% | 60% | 0.54 |
| Myalgia | 60% | 90% | 85% | 90% | 0.10 |
| Nausea | 25% | 50% | 30% | 30% | 0.44 |
| Peripheral edema | 20% | 10% | 30% | 20% | 0.48 |
| Vomiting | 5% | 25% | 20% | 10% | 0.35 |
| **SEVERITY** |
| Abdominal pain | 10% | 55% | 40% | 40% | 0.02 |
| Arthralgia | 45% | 80% | 75% | 60% | 0.10 |
| Asthenia/Fatigue | 60% | 90% | 90% | 80% | 0.06 |
| Constipation | 50% | 65% | 50% | 40% | 0.57 |
| Decreased appetite | 35% | 65% | 75% | 40% | 0.04 |
| Dysgeusia | 10% | 35% | 45% | 30% | 0.09 |
| Hand-foot syndrome | 20% | 40% | 55% | 40% | 0.16 |
| Headache | 50% | 60% | 45% | 20% | 0.23 |
| Myalgia | 55% | 85% | 80% | 60% | 0.15 |
| Nausea | 20% | 45% | 30% | 20% | 0.33 |
| Peripheral edema | 15% | 10% | 10% | 20% | 0.89 |
| Stomatitis | 10% | 35% | 40% | 40% | 0.12 |
| Xerostomia  | 25% | 70% | 60% | 70% | 0.02 |
| Vomiting | 5% | 25% | 15% | 10% | 0.39 |
| **INTERFERENCE ON DAILY ACTIVITIES** |
| Abdominal pain | 5% | 55% | 40% | 40% | <0.01 |
| Arthralgia  | 45% | 75% | 75% | 70% | 0.13 |
| Asthenia/Fatigue | 45% | 95% | 90% | 80% | <0.01 |
| Constipation | 25% | 55% | 45% | 40% | 0.29 |
| Decreased appetite | 30% | 60% | 70% | 40% | 0.06 |
| Headache | 45% | 60% | 40% | 10% | 0.07 |
| Myalgia | 55% | 85% | 70% | 60% | 0.19 |
| Peripheral edema | 15% | 10% | 10% | 20% | 0.89 |
| Stomatitis | 10% | 30% | 25% | 30% | 0.43 |
| **PRESENCE** |
| Dysphonia | 65% | 85% | 70% | 70% | 0.53 |
| Rash | 10% | 25% | 35% | 40% | 0.20 |

**Supplementary Table 2.** Percentage of patients perceiving the presence and/or any degree of frequency, severity, interference on daily activities of symptomatic AEs at baseline and during treatment with LEN (according to PRO-CTCAE questionnaires).

Abbreviations: AEs, adverse events; PRO-CTCAE, Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events; LEN, lenvatinib.